<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">PolarityTE, Inc.</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:285810c7-76d7-43a7-b1fe-06f5013135b0;id=40410</id>
  <rights
    type="text">Copyright 2018, PolarityTE, Inc.</rights>
  <updated>2018-08-09T12:30:00Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/sZ6T0tAkRbAS773nx-ZH2A==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/sZ6T0tAkRbAS773nx-ZH2A==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/08/09/1549705/0/en/PolarityTE-Inc-Announces-the-Addition-of-Ramses-Erdtmann-Managing-Partner-at-Point-Sur-Investors-and-Former-Executive-at-Pharmacyclics-and-David-Seaburg-Managing-Director-at-Cowen-.html</id>
    <title
      type="text">PolarityTE, Inc. Announces the Addition of Ramses Erdtmann, Managing Partner at Point Sur Investors and Former Executive at Pharmacyclics, and David Seaburg, Managing Director at Cowen and CNBC Contributor, to the Board of Directors</title>
    <published>2018-08-09T12:30:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/08/09/1549705/0/en/PolarityTE-Inc-Announces-the-Addition-of-Ramses-Erdtmann-Managing-Partner-at-Point-Sur-Investors-and-Former-Executive-at-Pharmacyclics-and-David-Seaburg-Managing-Director-at-Cowen-.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="left">SALT LAKE CITY, Aug.  09, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced the addition of Ramses (Rainer) Erdtmann and David Seaburg to the Board of Directors. Mr. Erdtmann is a Managing Partner at Point Sur Investors, a biotech investment fund focused on innovative therapies. Mr. Erdtmann previously worked at Pharmacyclics from 2008 through 2015 and remained with AbbVie as a consultant until 2016 post the acquisition of Pharmacyclics by AbbVie.  Mr. Seaburg is a Managing Director at Cowen, Inc. and a CNBC contributor, regularly commenting on the financial prospects of companies and interacting with management teams and institutional investors. <br></p>]]></content>
    <dc:identifier>1549705</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Thu, 09 Aug 2018 12:30 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/07/31/1544574/0/en/PolarityTE-Inc-Announces-Alain-Adam-as-Vice-President-of-Sales.html</id>
    <title
      type="text">PolarityTE, Inc. Announces Alain Adam as Vice President of Sales</title>
    <published>2018-07-31T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/07/31/1544574/0/en/PolarityTE-Inc-Announces-Alain-Adam-as-Vice-President-of-Sales.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, July  31, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL) today announced the appointment of Alain Adam as Vice President of Sales. Mr. Adam will lead the company’s continued development of its commercial strategy, sales force buildout, and execution.<br></p>]]></content>
    <dc:identifier>1544574</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Tue, 31 Jul 2018 12:02 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/07/25/1541947/0/en/PolarityTE-Inc-Provides-Commercial-Update.html</id>
    <title
      type="text">PolarityTE, Inc. Provides Commercial Update</title>
    <published>2018-07-25T13:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/07/25/1541947/0/en/PolarityTE-Inc-Provides-Commercial-Update.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, July  25, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company, today announced an update on the Company’s commercial progress. The Company’s first product, SkinTE, has transitioned into Stage 2 of commercialization and has continued to be successful in regenerating autologous full-thickness skin in the treatment of complex wounds including acute and chronic wounds, traumatic and surgical defects, burn wound reconstruction and skin graft replacement. With continued growing physician, facility, and VAC committee purchase agreement approvals, the Company has begun generating revenues while improving the lives of patients.<br></p>]]></content>
    <dc:identifier>1541947</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 25 Jul 2018 13:01 GMT</dc:modified>
    <dc:subject>Product / Services Announcement</dc:subject>
    <dc:subject>Calendar of Events</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/07/02/1532355/0/en/PolarityTE-Adds-Peter-Cohen-Former-Board-Member-of-the-NYSE-and-Chairman-and-CEO-of-Cowen-Inc-to-the-Board-of-Directors.html</id>
    <title
      type="text">PolarityTE Adds Peter Cohen, Former Board Member of the NYSE and Chairman and CEO of Cowen Inc., to the Board of Directors</title>
    <published>2018-07-02T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/07/02/1532355/0/en/PolarityTE-Adds-Peter-Cohen-Former-Board-Member-of-the-NYSE-and-Chairman-and-CEO-of-Cowen-Inc-to-the-Board-of-Directors.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="left">SALT LAKE CITY, July  02, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced that Peter Cohen will join PolarityTE’s Board of Directors. Mr. Cohen is well known within the investment community having previously served on the Board of Directors at the NYSE, as well as previously serving as the CEO and Chairman of the Board of Cowen Inc., Shearson Lehman Cowen, and Republic New York Securities.  Mr. Cohen is currently a Trustee of Mount Sinai Medical Center and has served on its board for approximately thirty years.  With the addition of Mr. Cohen, PolarityTE will increase the independence of its Board of Directors, with five of the Board’s seven Directors being independent. <br></p>]]></content>
    <dc:identifier>1532355</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Mon, 02 Jul 2018 12:01 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/27/1530272/0/en/PolarityTE-Provides-Update-on-Key-Opinion-Leader-Event-and-Addresses-Misleading-Report.html</id>
    <title
      type="text">PolarityTE Provides Update on Key Opinion Leader Event and Addresses Misleading Report</title>
    <published>2018-06-27T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/27/1530272/0/en/PolarityTE-Provides-Update-on-Key-Opinion-Leader-Event-and-Addresses-Misleading-Report.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="left">SALT LAKE CITY, June  27, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced that the Company hosted a successful meeting of key opinion leaders in New York City on June 25, 2018, addressing the use of SkinTE™ in complex wounds requiring cutaneous reconstruction. The three medical providers who presented at the event discussed the standard of care, limitations in the field, and their use of SkinTE, including patient outcomes and ongoing cases. The presentations emphasized the challenging nature of many of the complex wounds treated, and the encouraging and positive healing observed to date.<br></p>]]></content>
    <dc:identifier>1530272</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 27 Jun 2018 12:02 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/25/1528830/0/en/PolarityTE-Added-to-Russell-3000-and-Russell-2000-Indexes.html</id>
    <title
      type="text">PolarityTE Added to Russell 3000® and Russell 2000® Indexes</title>
    <published>2018-06-25T11:30:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/25/1528830/0/en/PolarityTE-Added-to-Russell-3000-and-Russell-2000-Indexes.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p>SALT LAKE CITY, June  25, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced that it is set to join the Russell 3000® and Russell 2000® Indexes at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on June 25, 2018, according to the final list of additions posted on June 22, 2018. <br></p>]]></content>
    <dc:identifier>1528830</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Mon, 25 Jun 2018 11:30 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/21/1527851/0/en/UPDATE-PolarityTE-Appoints-Paul-Mann-of-Highbridge-Capital-to-Chief-Financial-Officer.html</id>
    <title
      type="text">UPDATE - PolarityTE Appoints Paul Mann of Highbridge Capital to Chief Financial Officer</title>
    <published>2018-06-21T12:32:29Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/21/1527851/0/en/UPDATE-PolarityTE-Appoints-Paul-Mann-of-Highbridge-Capital-to-Chief-Financial-Officer.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS <pre>Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS</pre>]]></content>
    <dc:identifier>1527851</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Jun 2018 12:32 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/21/1527796/0/en/PolarityTE-Appoints-Paul-Mann-of-Highbridge-Capital-to-Chief-Financial-Officer.html</id>
    <title
      type="text">PolarityTE Appoints Paul Mann of Highbridge Capital to Chief Financial Officer</title>
    <published>2018-06-21T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/21/1527796/0/en/PolarityTE-Appoints-Paul-Mann-of-Highbridge-Capital-to-Chief-Financial-Officer.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS <pre>Current PolarityTE CFO John Stetson will Become Chief Investment Officer of the Company and President of a New Strategic Arm—PolarityIS</pre>]]></content>
    <dc:identifier>1527796</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Thu, 21 Jun 2018 12:01 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/18/1525740/0/en/PolarityTE-Provides-Corporate-Update-on-Company-Progress.html</id>
    <title
      type="text">PolarityTE Provides Corporate Update on Company Progress</title>
    <published>2018-06-18T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/18/1525740/0/en/PolarityTE-Provides-Corporate-Update-on-Company-Progress.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, June  18, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced an update on the Company’s progress.  Over the last several months PolarityTE has achieved multiple milestones and continues to execute on its strategy to commercialize SkinTE and position the Company for growth. Some recent items to note include:<br></p>]]></content>
    <dc:identifier>1525740</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Mon, 18 Jun 2018 12:00 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/05/1516997/0/en/PolarityTE-Announces-Pricing-of-Public-Follow-on-Offering-of-Common-Stock.html</id>
    <title
      type="text">PolarityTE Announces Pricing of Public Follow-on Offering of Common Stock</title>
    <published>2018-06-05T12:49:02Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/05/1516997/0/en/PolarityTE-Announces-Pricing-of-Public-Follow-on-Offering-of-Common-Stock.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p>SALT LAKE CITY, June  05, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced that the pricing of an underwritten public follow-on offering of approximately $55 million of shares of its common stock. PolarityTE has granted the underwriters for the offering a 30-day option to purchase up to approximately $8.2 million of additional shares of its common stock at the same price. The offering is expected to close on or about June 7, 2018, subject to satisfaction of customary closing conditions.<br></p>]]></content>
    <dc:identifier>1516997</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Tue, 05 Jun 2018 12:48 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/06/04/1516543/0/en/PolarityTE-Announces-Public-Offering-of-Common-Stock.html</id>
    <title
      type="text">PolarityTE Announces Public Offering of Common Stock</title>
    <published>2018-06-04T20:01:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/06/04/1516543/0/en/PolarityTE-Announces-Public-Offering-of-Common-Stock.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p>SALT LAKE CITY, June  04, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PolarityTE intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the price to the public, less underwriting discounts and commissions. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p>]]></content>
    <dc:identifier>1516543</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Mon, 04 Jun 2018 20:01 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
    <dc:subject>Stock Market News</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/30/1513845/0/en/PolarityTE-to-Present-at-the-Jefferies-2018-Global-Healthcare-Conference.html</id>
    <title
      type="text">PolarityTE to Present at the Jefferies 2018 Global Healthcare Conference</title>
    <published>2018-05-30T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/30/1513845/0/en/PolarityTE-to-Present-at-the-Jefferies-2018-Global-Healthcare-Conference.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, May  30, 2018  (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (Nasdaq:COOL) today announced it will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 2:30pm ET.  Denver M. Lough, MD, PhD, Chairman and CEO and Edward Swanson, MD, Executive VP and COO will provide an overview of PolarityTE’s science and platform technology, including SkinTE, a human cellular and tissue-based product derived from a patient’s own skin.<br></p>]]></content>
    <dc:identifier>1513845</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 30 May 2018 12:05 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/29/1513125/0/en/PolarityTE-to-host-Key-Opinion-Leader-Summit.html</id>
    <title
      type="text">PolarityTE to host Key Opinion Leader Summit</title>
    <published>2018-05-29T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/29/1513125/0/en/PolarityTE-to-host-Key-Opinion-Leader-Summit.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, May  29, 2018  (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (Nasdaq:COOL) today announced it will host a breakfast event in New York City with key opinion leaders (KOLs) to highlight the current treatment options for burns, wounds and skin defects, and the potential for new therapies in the field.<br></p>]]></content>
    <dc:identifier>1513125</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Tue, 29 May 2018 12:04 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/23/1510794/0/en/PolarityTE-Announces-Howard-Hechler-from-Smith-Nephew-as-the-New-Chief-Business-Officer.html</id>
    <title
      type="text">PolarityTE Announces Howard Hechler from Smith &amp; Nephew as the New Chief Business Officer</title>
    <published>2018-05-23T12:30:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/23/1510794/0/en/PolarityTE-Announces-Howard-Hechler-from-Smith-Nephew-as-the-New-Chief-Business-Officer.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="left">SALT LAKE CITY, May  23, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced the appointment of Howard Hechler as Chief Business Officer. Mr. Hechler will lead the Company’s M&amp;A and partnering efforts, as well as work with Executive Management to develop and execute the Company’s commercialization strategy. He will also work to align pipeline development efforts with the commercial strategy.<br></p>]]></content>
    <dc:identifier>1510794</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 23 May 2018 12:31 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/16/1507274/0/en/PolarityTE-Announces-Rich-Haerle-as-the-New-Vice-President-of-Investor-Relations-and-Corporate-Strategy.html</id>
    <title
      type="text">PolarityTE Announces Rich Haerle as the New Vice President of Investor Relations and Corporate Strategy</title>
    <published>2018-05-16T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/16/1507274/0/en/PolarityTE-Announces-Rich-Haerle-as-the-New-Vice-President-of-Investor-Relations-and-Corporate-Strategy.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[PolarityTE to open New York City satellite office for Investor Relations <pre>PolarityTE to open New York City satellite office for Investor Relations</pre>]]></content>
    <dc:identifier>1507274</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 16 May 2018 12:02 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/14/1501686/0/en/PolarityTE-Acquires-Operating-GLP-USDA-Preclinical-Biomedical-Research-Facility-and-Announces-Caroline-Garrett-DVM-from-Johns-Hopkins-as-Chief-Veterinary-Officer-at-Polarity.html</id>
    <title
      type="text">PolarityTE Acquires Operating GLP/USDA Preclinical Biomedical Research Facility and Announces Caroline Garrett DVM from Johns Hopkins as Chief Veterinary Officer at Polarity</title>
    <published>2018-05-14T12:30:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/14/1501686/0/en/PolarityTE-Acquires-Operating-GLP-USDA-Preclinical-Biomedical-Research-Facility-and-Announces-Caroline-Garrett-DVM-from-Johns-Hopkins-as-Chief-Veterinary-Officer-at-Polarity.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, May  14, 2018  (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (NASDAQ:COOL) announced the acquisition of a preclinical biomedical research facility in order to accelerate research and development of PolarityTE pipeline products. The facility is an already fully-functional, operational and profitable contract research organization (CRO) which is regulated and compliant under both Good Laboratory Practices (GLP) and United States Department of Agriculture (USDA) standards.<br></p>]]></content>
    <dc:identifier>1501686</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Mon, 14 May 2018 12:30 GMT</dc:modified>
    <dc:subject>Directors and Officers</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/09/1499493/0/en/PolarityTE-Accelerates-Sales-Team-for-Targeted-Regional-Release-of-SkinTE.html</id>
    <title
      type="text">PolarityTE™ Accelerates Sales Team for Targeted Regional Release of SkinTE™</title>
    <published>2018-05-09T12:30:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/09/1499493/0/en/PolarityTE-Accelerates-Sales-Team-for-Targeted-Regional-Release-of-SkinTE.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, May  09, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) announced today that it is growing its commercial presence by hiring dedicated sales representatives on the East Coast to accelerate the regional market release of SkinTE™. SkinTE is a human cellular and tissue-based product derived from a patient’s own skin, and is intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.<br></p>]]></content>
    <dc:identifier>1499493</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 09 May 2018 12:34 GMT</dc:modified>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/05/01/1493932/0/en/PolarityTE-Regenerates-Complex-Hierarchically-Organized-Corticocancellous-Bone-in-Preclinical-Studies.html</id>
    <title
      type="text">PolarityTE™ Regenerates Complex, Hierarchically-Organized, Corticocancellous Bone in Preclinical Studies</title>
    <published>2018-05-01T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/05/01/1493932/0/en/PolarityTE-Regenerates-Complex-Hierarchically-Organized-Corticocancellous-Bone-in-Preclinical-Studies.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, May  01, 2018  (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (NASDAQ:COOL) announced results demonstrating that the Company’s autologous bone product in development, OsteoTE<sup>TM</sup>, regenerated complex, hierarchically-organized, corticocancellous bone within critically-sized bone defects in standard preclinical large animal models. OsteoTE not only recapitulated the cortical and cancellous architecture of native uninjured bone, but also regenerated bone with function and composition reflective of native bone. The OsteoTE product, which utilizes the subject’s own bone, is prepared and used to treat the defect in less than 24 hours.<br></p>]]></content>
    <dc:identifier>1493932</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Tue, 01 May 2018 12:06 GMT</dc:modified>
    <media:content
      medium="image"
      type="image/png"
      width="600"
      url="https://resource.globenewswire.com/Resource/Download/2eb54b2e-c4f6-489f-a97a-12c2c3cde323">
      <media:text
        type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2018/05/01/1493932/0/en/PolarityTE-Regenerates-Complex-Hierarchically-Organized-Corticocancellous-Bone-in-Preclinical-Studies.html">
    <img src="https://resource.globenewswire.com/Resource/Download/2eb54b2e-c4f6-489f-a97a-12c2c3cde323" width="600" align="left" border="0" alt="OsteoTE Preclinical Results" title="OsteoTE preclinical results" />
  </a>
</p><br clear="all" />]]></media:text>
      <media:credit
        role="publishing company">GlobeNewswire Inc.</media:credit>
    </media:content>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/04/26/1488103/0/en/PolarityTE-Leadership-to-Participate-in-the-Symposium-on-Advanced-Wound-Care.html</id>
    <title
      type="text">PolarityTE Leadership to Participate in the Symposium on Advanced Wound Care</title>
    <published>2018-04-26T12:15:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/04/26/1488103/0/en/PolarityTE-Leadership-to-Participate-in-the-Symposium-on-Advanced-Wound-Care.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p>SALT LAKE CITY, April  26, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced attendance and participation in the Symposium on Advanced Wound Care Spring (SAWC Spring) Wound Healing Society (WHS) meeting being held in Charlotte, North Carolina through April 29, 2018.<br></p>]]></content>
    <dc:identifier>1488103</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Thu, 26 Apr 2018 12:15 GMT</dc:modified>
    <dc:subject>Calendar of Events</dc:subject>
    <dc:subject>Company Announcement</dc:subject>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2018/04/25/1487103/0/en/PolarityTE-Inc-Regains-Compliance-With-NASDAQ-Independent-Director-Requirement.html</id>
    <title
      type="text">PolarityTE, Inc. Regains Compliance With NASDAQ Independent Director Requirement</title>
    <published>2018-04-25T12:00:00Z</published>
    <updated>2024-11-26T19:37:02Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2018/04/25/1487103/0/en/PolarityTE-Inc-Regains-Compliance-With-NASDAQ-Independent-Director-Requirement.html" />
    <category
      term="Nasdaq:COOL"
      scheme="https://www.globenewswire.com/rss/stock" />
    <category
      term="US7310941080"
      scheme="https://www.globenewswire.com/rss/ISIN" />
    <content
      type="html"><![CDATA[<p align="justify">SALT LAKE CITY, April  25, 2018  (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced it has received formal notification from the Listing Qualifications Department of The NASDAQ Stock Market ("NASDAQ") notifying PolarityTE that it has regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2), the independent director requirement for continued listing on The NASDAQ Stock Market, with the appointment of Mr. Willie Bogan, and that the matter is now closed. PolarityTE’s common stock will continue to be listed on The NASDAQ Capital Market.  <br></p>]]></content>
    <dc:identifier>1487103</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>PolarityTE, Inc.</dc:contributor>
    <dc:modified>Wed, 25 Apr 2018 12:06 GMT</dc:modified>
    <dc:subject>Stock Market News</dc:subject>
  </entry>
</feed>